{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:33:32Z","timestamp":1790253212837,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40262-024-01450-8","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:49:22Z","timestamp":1737478162000},"page":"215-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1783-357X","authenticated-orcid":false,"given":"K. V.","family":"van der Heijden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5767-604X","authenticated-orcid":false,"given":"M. E.","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-4781","authenticated-orcid":false,"given":"J. W.","family":"Schoones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8159-0273","authenticated-orcid":false,"given":"M. J.","family":"van Esdonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5580-1153","authenticated-orcid":false,"given":"L. G. J. M.","family":"Borghans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-7314","authenticated-orcid":false,"given":"J. G. C.","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1444-7415","authenticated-orcid":false,"given":"J. M. A.","family":"van Gerven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"1450_CR1","doi-asserted-by":"publisher","first-page":"11207","DOI":"10.1073\/pnas.1902174116","volume":"166","author":"MJ Miller","year":"2019","unstructured":"Miller MJ, Albarracin-Jordan J, Moore C, Capriles JM. Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America. Proc Natl Acad Sci USA. 2019;166:11207\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1450_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.adf0435","volume":"379","author":"MV Vargas","year":"2023","unstructured":"Vargas MV, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379:700\u20136.","journal-title":"Science"},{"key":"1450_CR3","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","volume":"25","author":"AC Kwan","year":"2022","unstructured":"Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci. 2022;25:1407\u201319.","journal-title":"Nat Neurosci"},{"key":"1450_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01389-z","author":"AE Calder","year":"2022","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2022. https:\/\/doi.org\/10.1038\/s41386-022-01389-z.","journal-title":"Neuropsychopharmacology"},{"key":"1450_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1124\/jpet.106.108415","volume":"320","author":"T Cormaci","year":"2007","unstructured":"Cormaci T, Mori T, Hayashi TS. Protein kinase A activation down-regulates, whereas extracellular signal-regulated kinase activation up-regulates sigma-1 receptors in B-104 cells: implication for neuroplasticity. J Pharmacol Exp Ther. 2007;320:202\u201310.","journal-title":"J Pharmacol Exp Ther"},{"key":"1450_CR6","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"R Moliner","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032\u201341.","journal-title":"Nat Neurosci"},{"key":"1450_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/d41586-021-00187-9","volume":"589","author":"P Tullis","year":"2021","unstructured":"Tullis P. The rise of psychedelic psychiatry. Nature. 2021;589:506\u20139.","journal-title":"Nature"},{"key":"1450_CR8","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1177\/0269881118780612","volume":"32","author":"T Noorani","year":"2018","unstructured":"Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW. Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts. J Psychopharmacol. 2018;32:756\u201369.","journal-title":"J Psychopharmacol"},{"key":"1450_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12985","author":"E Argento","year":"2019","unstructured":"Argento E, Capler R, Thomas G, Lucas P, Tupper KW. Exploring ayahuasca-assisted therapy for addiction: a qualitative analysis of preliminary findings among an Indigenous community in Canada. Drug Alcohol Rev. 2019. https:\/\/doi.org\/10.1111\/dar.12985.","journal-title":"Drug Alcohol Rev"},{"key":"1450_CR10","doi-asserted-by":"publisher","DOI":"10.2174\/15733998113099990003","author":"G Thomas","year":"2013","unstructured":"Thomas G, Lucas P, Capler NR, Tupper KW, Martin G. Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr Drug Abuse Rev. 2013. https:\/\/doi.org\/10.2174\/15733998113099990003.","journal-title":"Curr Drug Abuse Rev"},{"key":"1450_CR11","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","volume":"47","author":"DC D\u2019Souza","year":"2022","unstructured":"D\u2019Souza DC, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology. 2022;47:1854\u201362.","journal-title":"Neuropsychopharmacology"},{"key":"1450_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000438","volume":"2","author":"JC Bouso","year":"2022","unstructured":"Bouso JC, Andi\u00f3n \u00d3, Sarris JJ, Scheidegger M, T\u00f3foli LF, Opaleye ES, Schubert V, Perkins D. Adverse effects of ayahuasca: results from the Global Ayahuasca Survey. PLOS Glob Public Health. 2022;2: e0000438.","journal-title":"PLOS Glob Public Health."},{"key":"1450_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231196877","author":"LX Luan","year":"2023","unstructured":"Luan LX, et al. Psychological and physiological effects of extended DMT. J Psychopharmacol. 2023. https:\/\/doi.org\/10.1177\/02698811231196877.","journal-title":"J Psychopharmacol"},{"key":"1450_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41398-023-02477-4","volume":"23","author":"SB Vogt","year":"2023","unstructured":"Vogt SB, Ley L, Erne L, Straumann I, Becker AM, Klaiber A, Holze F, Vandersmissen A, Mueller L, Duthaler U, Rudin D, Luethi D, Varghese N, Eckert A. Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Transl Psychiatry. 2023;23:172.","journal-title":"Transl Psychiatry"},{"key":"1450_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s13318-023-00822-y","volume":"48","author":"M Good","year":"2023","unstructured":"Good M, et al. Pharmacokinetics of N, N-dimethyltryptamine fumarate in humans. Eur J Drug Metab Pharmacokinet. 2023;48:311\u201327.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1450_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.drudis.2011.12.020","volume":"17","author":"P Morgan","year":"2012","unstructured":"Morgan P, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today. 2012;17:419\u201324.","journal-title":"Drug Discov Today"},{"key":"1450_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev-pharmtox-011613-135918","volume":"55","author":"AF Cohen","year":"2015","unstructured":"Cohen AF, Burggraaf J, Van Gerven JMA, Moerland M, Groeneveld GJ. The use of biomarkers in human pharmacology (Phase I) studies. Annu Rev Pharmacol Toxicol. 2015;55:55\u201374.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1450_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.drudis.2020.10.019","volume":"26","author":"SS Wu","year":"2021","unstructured":"Wu SS, et al. Reviving an R&D pipeline: a step change in the Phase II success rate. Drug Discov Today. 2021;26:308\u201314.","journal-title":"Drug Discov Today"},{"key":"1450_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","volume":"126","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Gatch MB. Neuropharmacology of N, N-dimethyltryptamine. Brain Res Bull. 2016;126:74\u201388.","journal-title":"Brain Res Bull"},{"key":"1450_CR20","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1021\/acschemneuro.8b00101","volume":"9","author":"LP Cameron","year":"2018","unstructured":"Cameron LP, Olson DE. Dark classics in chemical neuroscience: N, N-dimethyltryptamine (DMT). ACS Chem Neurosci. 2018;9:2344\u201357.","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"1450_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med. 2009;151(4):264\u20139.","journal-title":"Ann Int Med"},{"key":"1450_CR22","unstructured":"Otto M, van der Heijden K, Makai-B\u00f6l\u00f6ni S, Borghans L, J G. Clinical pharmacokinetics of N, N-dimethyltryptamine (DMT) and psilocybin in humans: a systematic review. PROSPERO. 2023:CRD4202338."},{"key":"1450_CR23","unstructured":"Rohatgi A. WebPlotDigitizer. 2022. https:\/\/automeris.io\/WebPlotDigitizer."},{"key":"1450_CR24","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. 2020."},{"issue":"11\u2013107","key":"1450_CR25","first-page":"S65","volume":"42","author":"WS Denney","year":"2015","unstructured":"Denney WS, Duvvuri S, Buckeridge C. Simple, automatic noncompartmental analysis: the PKNCA R package. J Pharmacokinet Pharmacodyn. 2015;42(11\u2013107):S65.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1450_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1055\/s-2005-916185","volume":"38","author":"E Gouzoulis-Mayfrank","year":"2005","unstructured":"Gouzoulis-Mayfrank E, et al. Psychological effects of (S)-ketamine and N, N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry. 2005;38:301\u201311.","journal-title":"Pharmacopsychiatry"},{"key":"1450_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2022.123534","volume":"1213","author":"D Luethi","year":"2022","unstructured":"Luethi D, et al. Liquid chromatography-tandem mass spectrometry method for the bioanalysis of N, N-dimethyltryptamine (DMT) and its metabolites DMT-N-oxide and indole-3-acetic acid in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2022;1213: 123534.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"1450_CR28","unstructured":"Benway T. Results from the phase 1 small pharma trial of SPL026 in psychedelic-naive healthy volunteers. ICNS. 2022:19."},{"key":"1450_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-51974-4","volume":"9","author":"C Timmermann","year":"2019","unstructured":"Timmermann C, et al. Neural correlates of the DMT experience assessed with multivariate EEG. Sci Rep. 2019;9:1\u201313.","journal-title":"Sci Rep"},{"key":"1450_CR30","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1111\/cts.13410","volume":"15","author":"E Eckern\u00e4s","year":"2022","unstructured":"Eckern\u00e4s E, Timmermann C, Carhart-Harris R, R\u00f6shammar D, Ashton M. Population pharmacokinetic\/pharmacodynamic modeling of the psychedelic experience induced by N, N-dimethyltryptamine\u2014implications for dose considerations. Clin Transl Sci. 2022;15:2928\u201337.","journal-title":"Clin Transl Sci"},{"key":"1450_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114642","volume":"212","author":"E Eckern\u00e4s","year":"2022","unstructured":"Eckern\u00e4s E, et al. Development and application of a highly sensitive LC-MS\/MS method for simultaneous quantification of N, N-dimethyltryptamine and two of its metabolites in human plasma. J Pharm Biomed Anal. 2022;212: 114642.","journal-title":"J Pharm Biomed Anal"},{"key":"1450_CR32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/0006-3223(95)00200-6","volume":"39","author":"RJ Strassman","year":"1996","unstructured":"Strassman RJ, Qualls CR, Berg LM. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biol Psychiatry. 1996;39:784\u201395.","journal-title":"Biol Psychiatry"},{"key":"1450_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ, Qualls CR. Dose-response study of N, N-dimethyltryptamine in humans: I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994;51:85\u201397.","journal-title":"Arch Gen Psychiatry"},{"key":"1450_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2016.00211","volume":"7","author":"AR Gallimore","year":"2016","unstructured":"Gallimore AR, Strassman RJ. A model for the application of target-controlled intravenous infusion for a prolonged immersive DMT psychedelic experie. Front Pharmacol. 2016;7:1\u201311.","journal-title":"Front Pharmacol"},{"key":"1450_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00421376","volume":"38","author":"J Kaplan","year":"1974","unstructured":"Kaplan J, et al. Blood and urine levels of N, N-dimethyltryptamine following administration of psychoactive dosages to human subjects. Psychopharmacologia. 1974;38:239\u201345.","journal-title":"Psychopharmacologia"},{"key":"1450_CR36","doi-asserted-by":"publisher","first-page":"970","DOI":"10.2967\/jnumed.110.083246","volume":"52","author":"AA Vitale","year":"2011","unstructured":"Vitale AA, et al. In vivo long-term kinetics of radiolabeled N, N-dimethyltryptamine and tryptamine. J Nucl Med. 2011;52:970\u20137.","journal-title":"J Nucl Med"},{"key":"1450_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00018-024-05353-6","volume":"81","author":"K Egger","year":"2024","unstructured":"Egger K, Aicher HD, Cumming P, Scheidegger M. Neurobiological research on N, N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors. Cell Mol Life Sci. 2024;81:395.","journal-title":"Cell Mol Life Sci"},{"key":"1450_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.886408","volume":"13","author":"I Berlowitz","year":"2022","unstructured":"Berlowitz I, Egger K, Cumming P. Monoamine oxidase inhibition by plant-derived \u03b2-carbolines; implications for the psychopharmacology of tobacco and ayahuasca. Front Pharmacol. 2022;13: 886408.","journal-title":"Front Pharmacol"},{"key":"1450_CR39","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/dta.1344","volume":"4","author":"J Riba","year":"2012","unstructured":"Riba J, McIlhenny EH, Valle M, Bouso JC, Barker SA. Metabolism and disposition of N, N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca. Drug Test Anal. 2012;4:610\u20136.","journal-title":"Drug Test Anal"},{"key":"1450_CR40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/dta.2197","volume":"10","author":"AT Caspar","year":"2018","unstructured":"Caspar AT, et al. Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MS(n), and LC-HR-MS\/MS. Drug Test Anal. 2018;10:184\u201395.","journal-title":"Drug Test Anal"},{"key":"1450_CR41","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/ph13110334","volume":"13","author":"AM Brito-da-Costa","year":"2020","unstructured":"Brito-da-Costa AM, Dias-da-Silva D, Gomes NGM, Dinis-Oliveira RJ, Madureira-Carvalho \u00c1. Toxicokinetics and toxicodynamics of ayahuasca alkaloids N, N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine: clinical and forensic impact. Pharmaceuticals. 2020;13:334.","journal-title":"Pharmaceuticals"},{"key":"1450_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2021.111516","volume":"197","author":"C Sanfilippo","year":"2021","unstructured":"Sanfilippo C, et al. Sex-dependent monoamine oxidase isoforms expression patterns during human brain ageing. Mech Ageing Dev. 2021;197: 111516.","journal-title":"Mech Ageing Dev"},{"key":"1450_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.neuro.2022.09.008","volume":"93","author":"SW Hong","year":"2022","unstructured":"Hong SW, Teesdale-Spittle P, Page R, Truman P. A review of monoamine oxidase (MAO) inhibitors in tobacco or tobacco smoke. Neurotoxicology. 2022;93:163\u201372.","journal-title":"Neurotoxicology"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01450-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01450-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01450-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:47:45Z","timestamp":1738255665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01450-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1450"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01450-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"24 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"No conflict of interest was present.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data presented in this study were acquired from authors upon request or extracted from published reports, which have been referenced. Gathered data therefore are not directly available from the authors but may available upon request of the referred authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"No clinical study was conducted.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No clinical study was conducted.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No clinical study was conducted.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Code for the non-compartmental analysis is available upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"K.V.v.H and M.E.O. designed the study, searched, acquired and analyzed the data, and drafted the manuscript. J.W.S. designed the search strategy and searched the literature. J.W.S, M.J.v.E., L.B., G.J., J.G.C.H., and J.G. critically reviewed the manuscript. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}